AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

Among some other larger deals, AbbVie acquired ImmunoGen last year ... see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

ImmunoGen's Elahere for ovarian cancer has been approved for initial treatments and is on track for approval for numerous others. 7 Space Stocks Growth-Oriented Investors Can Buy Now AbbVie ...